Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74.
Lu Y-C, Robbins PF. Cancer immunotherapy targeting neoantigens. Semin Immunol. 2016;28(1):22-27.
Hause RJ, Pritchard CC, Shendure J, Salipante SJ. Classification and characterization of microsatellite
instability across 18 cancer types. Nat Med. 2016. doi:10.1038/nm.4191.
Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27(1):9-14.
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape
of tumor mutational burden. Genome Med. 2017;9(1):34. doi:10.1186//s13073-017-0424-2.
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Ann Oncol.
2016;27(8):1492-1504.
Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, et al. Inactivation of DNA repair triggers
neoantigen generation and impairs tumour growth. Nature. 2017;552:116-20.
Bobisse S, Foukas PG, Coukos G, Harari A. Neoantigen-based cancer immunotherapy. Ann Transl Med.
2016;4(14):262.
Efremova M, Finotello F, Rieder D, Trajanoski Z. Neoantigens generated by individual mutations and their
role in cancer immunity and immunotherapy. Front Immunol. 2017;8:1679. doi:10.3389/fimmu.2017.01679.
Chabanon RM, Pedrero M, Lefebvre C, Marabelle A, Soria JC, Postel-Vinay S. Mutational landscape and
sensitivity to immune checkpoint blockers. Clin Cancer Res. 2016;22(17):4309-4321.
Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer
immunotherapy. J Immunother Cancer. 2016;4:3. doi:10.1186/s40425-016-0107-3.